top of page

Independent & community-funded.  Ufloxed receives no government or pharmaceutical funding — our £2.99/month membership simply covers the cost of keeping this
resource online and we promise to maintain  committed to making this website as helpful and informative as possible, continually improving and updating it for the future.

The Global Impact

How many people
have been floxed?

Honestly - nobody knows.

There is no reliable worldwide count of people living with Fluoroquinolone-Associated Disability. But after decades of global prescribing, the official estimates and independent research point to a problem that is anything but small — and almost certainly under-counted.

Some researchers and patient advocates ask whether this could be one of the largest hidden harms in the history of modern medicine. What is certain: until the world properly counts it, every figure is an estimate — and every estimate deserves scrutiny.

WhatsApp Image 2026-11-18 at 14.57.56.jpeg
The hidden effects: you can be affected without knowing it.
Fluoroquinolones act at the cellular level — researchers have compared some of their effects to those of chemotherapy agents. That means damage can begin silently, inside mitochondria and connective tissue, long before any symptom appears. Some people feel fine after a course yet carry subtle cellular effects they never connect to the antibiotic. The visible cases may be only part of the picture.
What regulators do tell us

In January 2024, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) published a landmark estimate: serious, disabling, potentially long-lasting or irreversible adverse reactions are estimated to occur in 1–10 people per 10,000 treated with systemic or inhaled fluoroquinolones — equivalent to 0.01%–0.1% of patients. The MHRA also acknowledges that the precise frequency cannot be established from available data.

 

Source: MHRA Drug Safety Update, January 2024 (GOV.UK).

​

PEOPLE TREATED

100 million
1-10

people per 10,000 treated 

0.01% – 0.1% of patients · serious, disabling or potentially irreversible reactions

Sounds rare — until you multiply it by the hundreds of millions of courses prescribed worldwide, year after year, decade after decade.

ESTIMATED SERIOUS REACTIONS

10,000-1000,000

These figures represent estimated serious reactions at the MHRA rate — not confirmed cases of chronic FQAD, for which no prevalence data currently exists.

What the studies show — and what they don't

UNITED STATES . 2020

= 0. 2%

Antibiotic - associated disability study

Among 119,653 fluoroquinolone-exposed patients studied after matching, 264 met the definition of antibiotic-associated disability — an estimated frequency of about 0.2%. However, a similar frequency appeared in patients taking comparator antibiotics, so this does not prove all cases were caused by fluoroquinolones.

 

Published 2020 · PubMed Central

FINLAND . 2022

11,405

Modelled national harm estimate

Researchers estimated that between 2008 and 2019, fluoroquinolones were associated with 11,405 serious adverse reactions and 3,884 deaths in Finland. These were modelled estimates spanning several reaction types — including severe infections, tendon ruptures and liver injuries — not confirmed FQAD cases.

 

Published 2022 · PubMed Central

WORLDWIDE EXPOSURE

800 million

A glimpse of total scale

A CDC document discusses a reported figure of 800 million combined worldwide fluoroquinolone uses from a single manufacturer. It illustrates the sheer scale of exposure — but it is not a verified worldwide patient count.

 

CDC document

Three populations that must not be confused 

Floxed patients

People experiencing suspected adverse effects after fluoroquinolone exposure.

Serious adverse reactions

People experiencing serious or disabling reactions, as defined by regulators.

Chronic FQAD

People with persistent, multisystem symptoms and lasting disability.

These groups overlap, but they are not interchangeable — and there is currently insufficient epidemiological evidence to calculate how many people worldwide live with chronic FQAD.

Why is FQAD so under-recognised?

Delayed onset hides the link

Symptoms can begin weeks or months after the last tablet, so neither patient nor doctor connects them to the antibiotic.

Reporting systems capture a fraction

Voluntary adverse-reaction reporting is known to undercount. Many patients never report; many reports are never investigated.

Symptoms look like other conditions

Fatigue, tendon pain, neuropathy and anxiety each have more common explanations — FQAD is rarely considered first.

No diagnostic test exists

Without a biomarker, cases depend on clinical judgement — and clinicians unfamiliar with FQAD cannot count what they cannot name.

“Millions of people worldwide have been exposed to fluoroquinolone antibiotics. The true number experiencing serious, persistent or disabling adverse reactions remains unknown. Better international research is urgently needed.”

 

The statement we stand behind — no inflated figures, no false precision.

If the world won't count us, we will help count ourselves.

One of the most valuable projects an international platform can build is aworldwide voluntary patient survey — collecting anonymised information about symptoms, antibiotic exposure, duration of illness and recovery experiences. It cannot establish global prevalence by itself, but it can identify research priorities and give patients a stronger collective voice.

This is a founding goal of Ufloxed — alongside international epidemiological research and, one day, a properly governed worldwide patient registry.

Explore the numbers behind the numbers

See what we know — country by country — about how widely these antibiotics have been prescribed.

bottom of page